Is a complete CCCC research report available?

No complete published report is available for C4 Therapeutics, Inc. (CCCC) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

C4 Therapeutics, Inc. (CCCC)

NASDAQ: CCCC · USD

$3.66

+0.14 (+4.0%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first CCCC analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	404.7M
Revenue (ttm)	34.9M
Net income (ttm)	-103.8M
EPS (ttm)	-$1.07
Shares out	110.6M
Volume	3,149,051
Beta	2.91
Price target	$13.3	+264.2%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 34.9M
Net income (ttm): -103.8M
EPS (ttm): -$1.07
Market cap: 404.7M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All CCCC indicators

Market & fundamental data

Available fields

215

Groups with data

Currency

USD

Showing 215 of 215 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001662579
Company name	C4 Therapeutics, Inc.
Country	United States
Country code	US
Cusip	12529R107
Employees	104
Employees Change	-6%
Employees Change Percent	-5.45
Enterprise value	$194.9M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2020-10-02
Isin	US12529R1077
Last refreshed	2026-07-31
Market cap	$404.7M
Market cap category	Small-Cap
Price	$3.66
Price currency	USD
Rev Per Employee	335,201.92x
Sector	Healthcare
Sector PE	45.64
Sector PE Fwd	24.21
Sic	2836
Symbol	CCCC
Website	https://www.c4therapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-25.65%
EV Sales Forward	12.04x
EV/Sales	5.59x
FCF yield	-23.73%
P/B ratio	1.63x
P/S ratio	11.61x
PS Forward	25.01x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-320.53%
EBITDA Margin	-315.08%
Gross margin	78.34%
Gross Profit	$27.3M
Gross Profit Growth	-42.13%
Gross Profit Growth Q	7.31%
Net Income	$-103.8M
Net Income Growth Quarters	2%
Net Income Growth Years	2%
Pretax Margin	-297.41%
Profit Margin	-297.76%
Profit Per Employee	$-998,087
ROA	-19.88
Roa5y	-17.74
ROCE	-38.2
ROE	-48.35
Roe5y	-40.46
ROIC	-23.34

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	62.72%
Cagr3y	-0.89%
Cagr5y	-39.09%
EPS Growth Quarters	2
EPS Growth Years	2
Revenue Growth	-12.37x
Revenue Growth Q	-15x
Revenue Growth Years	2x
Revenue Growth3 Y	8.62x
Revenue Growth5 Y	0.62x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.11
Assets	$328.9M
Cash	$235.7M
Current Assets	$245.4M
Current Liabilities	$27.2M
Debt	$58.4M
Debt Equity	$0.25
Equity	$234.2M
Liabilities	$94.6M
Long Term Assets	$83.5M
Long Term Liabilities	$67.4M
Net Cash	$209.8M
Net Cash By Market Cap	$51.85
Net Cash Growth	23.18%
Net Debt Equity	$-0.9
Tangible Book Value	$234.2M
Tangible Book Value Per Share	$2.25
WACC	17.7

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	9
Net Working Capital	$-11M
Quick ratio	8.75
Working Capital	$218.1M
Working Capital Turnover	$0.17

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-38.2%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	62.67%
200-day SMA	2.85
3Y total return	-2.66%
50-day SMA	3.91
50-day SMA vs 200-day SMA	50over200
5Y total return	-91.62%
All Time High	51.21
All Time High Change	-92.85%
All Time High Date	2021-09-23
All Time Low	1.06
All Time Low Change	245.28%
All Time Low Date	2023-12-06
ATR	0.3
Beta	2.91
Beta1y	2.59
Beta2y	2.48
Ch YTD	91.62
High	3.69
High52	5.17
High52 Date	2026-06-30
High52ch	-29.21%
Low	3.52
Low52	1.69
Low52 Date	2026-02-05
Low52ch	116.57%
Ma50ch	-6.27%
Premarket Change Percent	1.14
Premarket Price	$3.56
Premarket Volume	2,228
Price vs 200-day SMA	28.38%
RSI	46.2
RSI Monthly	48.6
RSI Weekly	56.69
Sharpe ratio	0.92x
Sortino ratio	1.75
Total Return	-38.2%
Tr YTD	91.62
Tr1m	-15.86%
Tr1w	0.27%
Tr3m	42.97%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	7
Analyst Count Top	5
Analyst Price Target Top	$9.5
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.23
Earnings Revenue Estimate	4,400,000x
Earnings Revenue Estimate Growth	-31.92x
Operating Income	$-103.1M
Operating margin	-295.8
Price target	$13.33
Price Target Change	$264
Price Target Change Top	$160

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	83,707,130%
Float Percent	75.71%
Shares Insiders	1.14%
Shares Institutions	76.12%
Shares Out	110,567,222
Shares Qo Q	7.96%
Shares Yo Y	38.2%
Short Float	28.45%
Short Ratio	5.82
Short Shares	21.54

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-112.3M
Adjusted OCF	-111,616,000
Average Volume	3,008,807x
Bv Per Share	2.25
CAPEX	$-671,000
Ch1m	-15.86
Ch1w	0.27
Ch1y	62.67
Ch3m	42.97
Ch3y	-2.66
Ch5y	-91.62
Ch6m	86.74
Change	3.98%
Change From Open	3.68
Close	3.52
Days Gap	0.28
Depreciation Amortization	1,907,000
Dollar Volume	11,525,526.7
Earnings Date	2026-08-06
Earnings Time	bmo
EBIT	$-115.2M
EBITDA	$-113.3M
EPS	$-1.07
F Score	2
FCF	$-96M
FCF EV Yield	-49.28x
FCF Per Share	$-0.87
Financing CF	126,907,000
Fiscal Year End	December
Founded	2,015
Income Tax	$121,000
Investing CF	-21,573,000
Ipr	-80.74
Iprfo	-86.24
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-12
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-26
Ma150	2.99
Ma150ch	22.33%
Ma20	3.83
Ma20ch	-4.49%
Net CF	9,981,000
Next Earnings Date	2026-08-10
Open	3.53
Optionable	Yes
Position In Range	82.86
Post Close	3.66
Postmarket Change Percent	-0.82
Postmarket Price	$3.63
Ppne	43,582,000
Pre Close	3.52
Price Date	2026-07-30
Ptbv Ratio	1.73
Relative Volume	1.05x
Revenue	34,861,000x
SBC By Revenue	46.65x
Share Based Comp	16,263,000
Tax By Revenue	0.35x
Tr6m	86.74%
Us State	Massachusetts
Volume	3,149,051
Z Score	-2.24

C4 Therapeutics, Inc. (CCCC)

Coverage state: Market snapshot only — no published research

Generate the first CCCC analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · CCCC

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All CCCC indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on CCCC

Frequently asked questions